FDAsafety guidance77% confidence
FDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ophthalmology) as Fluorescein Sodium; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA207549. Sponsor: AMNEAL. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: METHYLPREDNISOLONE SODIUM SUCCINATE.
Supporting Context
- Therapeutic area
- Ophthalmology · Diagnostic Agent
- Sub-indication
- Ophthalmology
Related signal: FDA Grants Approval for Zydus Lifesciences' Fluorescein Sodium Application